Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Fish and Richardson
Mallinckrodt
Fuji
Chubb
Dow
Daiichi Sankyo
Cantor Fitzgerald
Citi
Deloitte

Generated: August 19, 2017

DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXOSMITHKLINE CONS, and when can generic versions of GLAXOSMITHKLINE CONS drugs launch?

GLAXOSMITHKLINE CONS has eleven approved drugs.

There are twelve US patents protecting GLAXOSMITHKLINE CONS drugs.

There are three hundred and twenty-four patent family members on GLAXOSMITHKLINE CONS drugs in forty-eight countries.

Summary for Applicant: Glaxosmithkline Cons

Patents:12
Tradenames:10
Ingredients:10
NDAs:11
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons
ALLI
orlistat
CAPSULE;ORAL021887-001Feb 7, 2007OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
NICORETTE
nicotine polacrilex
TROCHE/LOZENGE;ORAL022360-002May 18, 2009OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
LAMISIL
terbinafine
GEL;TOPICAL020846-001Apr 29, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Glaxosmithkline Cons

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons
LAMISIL
terbinafine
GEL;TOPICAL020846-001Apr 29, 1998► Subscribe► Subscribe
Glaxosmithkline Cons
NICORETTE
nicotine polacrilex
TROCHE/LOZENGE;ORAL022360-002May 18, 2009► Subscribe► Subscribe
Glaxosmithkline Cons
EXCEDRIN (MIGRAINE)
acetaminophen; aspirin; caffeine
TABLET;ORAL020802-001Jan 14, 1998► Subscribe► Subscribe
Glaxosmithkline Cons
LAMISIL
terbinafine
GEL;TOPICAL020846-001Apr 29, 1998► Subscribe► Subscribe
Glaxosmithkline Cons
LAMISIL
terbinafine hydrochloride
SOLUTION;TOPICAL020749-001Oct 17, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GLAXOSMITHKLINE CONS drugs

Drugname Dosage Strength Tradename Submissiondate
nicotine polacrilex
Gum2 mg
NICORETTE
1/22/2013
nicotine polacrilex
Gum4 mg
NICORETTE
1/22/2013
orlistat
Capsules60 mg
ALLI
9/8/2010

Non-Orange Book Patents for Glaxosmithkline Cons

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,787,532 Formulation containing anti-inflammatory androstane derivatives► Subscribe
7,629,335Anti-inflammatory androstane derivative► Subscribe
6,537,983 Anti-inflammatory androstane derivatives► Subscribe
7,592,329Crystalline complexes of fluticasone-2-furoate► Subscribe
7,798,368Fluid dispensing device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Glaxosmithkline Cons Drugs

Country Document Number Estimated Expiration
Eurasian Patent Organization005992► Subscribe
Norway20075376► Subscribe
Denmark2285411► Subscribe
European Patent Office1471884► Subscribe
Germany60330765► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Glaxosmithkline Cons Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C011/2008Ireland► SubscribeSPC011/2008: 20081105, EXPIRES: 20230110
C0042Belgium► SubscribePRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
6Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Dow
Novartis
Merck
McKesson
Daiichi Sankyo
Fish and Richardson
Teva
Queensland Health
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot